Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...

German Merck KGaA’s recently acquired subsidiary SpringWorks Therapeutics today announced that long-term efficacy and safety data from the Phase III DeFi trial of Ogsiveo (nirogacestat) were in the ...

Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Martin ...

SpringWorks Therapeutics Inc. shares SWTX were on track for a record percentage gain on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of ...

German pharmaceuticals and technology company Merck KGaA gave a guidance for 2026 that sent its shares falling during its ...

While the M&A emphasis is currently on life sciences, a business unit which sells products used in R&D and manufacturing ...

Merck officially opened its €150m filtration manufacturing facility at Blarney Business Park in Cork last month. The Blarney facility is part of Merck’s largest life science investment to date in ...

GERMAN pharmaceuticals and technology company Merck KGaA slightly improved its midterm guidance for its health care business ahead of its capital markets day on Thursday.

DelveInsight's Anaplastic Astrocytoma Market Insights report includes a comprehensive understanding of current treatment ...

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data ...